Product

MyopiaX^®

MyopiaX^® is a smartphone application that administers a therapeutic intervention developed to slow the progression of myopia in children and adolescents. Used together with a virtual reality headset and Bluetooth controller, MyopiaX^® is an innovative, non-invasive approach to control myopia that is engaging and easy for children to use.

Each session with MyopiaX delivers selective ocular light stimulation through VR game. Use the MyopiaX® to monitor session completion and performance to optimize treatment compliance. Learn more about how MyopiaX® works on our Science page.

Our App

MyopiaX^® is designed for everyday life, leveraging consumer technology to administer selective ocular light stimulation through an interactive digital experience. Developed to deliver an active treatment, MyopiaX^® adheres to medical device regulations. The MyopiaX^®’s intuitive app interface makes at-home use simple, transforming twice-daily sessions into a child-friendly, therapeutic routine.

Child-Friendly Alternative

MyopiaX^® is specifically designed for children, informed by extensive usability studies with children and families. Leveraging consumer electronics and engaging digital content, we envision MyopiaX^® as an accessible and enjoyable treatment to slow the progression of myopia. Usability studies confirmed that MyopiaX^® is fun and easy for children to use under minimal supervision. Our extensive studies exceed the standard requirements to evaluate the usability of a medical device as it relates to safety. These studies drive the continuous improvement of MyopiaX^®, with usability engineering activities designed to enhance both the technical components and the overall user experience for children.

Developed According to Medical Device Standards

MyopiaX^® is developed to meet medical device safety standards for everyday use, backed by comprehensive technical documentation covering all essential norms, including software lifecycle management (EN 62304) and risk management (ISO 14971). Our goal is to achieve certification as a medical device under European and international regulations. Results from ongoing research and clinical trials will support regulatory activities to certify MyopiaX^® as a safe, effective treatment for myopia control.

More About MyopiaX^®

MyopiaX^® is designed to be used daily. Each session lasts for several minutes and delivers selective ocular light stimulation while users interact with virtual reality content. The virtual reality content includes mini-games, a customizable avatar, and interactive quests. A variety of fun and educational content means that MyopiaX^® is always engaging for users.

Contact

Reach Us

Job Offers

Info

Imprint

Privacy Policy

Our Partners

Dopavision is funded as part of the BMBF’s Industry-in-Clinic Platform Program (FKZ: 13GW0625)

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Product

MyopiaX^®